Fentanyl test strips can be valuable harm-reduction tools, but a positive strip is not the same thing as a definitive laboratory identification of fentanyl. A 2021 laboratory study illustrates why concentration, sample preparation, and assay design matter when a test developed for urine is used on dissolved street-drug material.
Lockwood and colleagues studied the BTNX Rapid Response fentanyl test strip, a lateral-flow immunoassay with a stated fentanyl detection threshold of 20 ng/mL. These strips use antibodies to produce a qualitative result. In their traditional application, the specimen is urine. In harm-reduction settings, however, a small amount of powder or residue may be dissolved directly in water. That different preparation can expose the antibody to other compounds at concentrations measured in milligrams per milliliter rather than the much lower concentrations expected in urine.
The investigators tested four pharmaceuticals—diphenhydramine, alprazolam, gabapentin, and a naloxone/buprenorphine product—and three stimulants: cocaine hydrochloride, methamphetamine, and MDMA. Test solutions ranged from 0.2 to 20 mg/mL. Photographs of the strips were analyzed with ImageJ to quantify control- and test-line intensity rather than relying only on visual judgment.
At concentrations of 1 mg/mL or greater, MDMA, methamphetamine, and diphenhydramine produced results that the investigators classified as false positives for fentanyl. The problem was concentration dependent. The study did not show that an ordinary therapeutic or biological concentration of MDMA “turns into” fentanyl, nor did it show that every positive strip from an MDMA sample is false. It showed that sufficiently concentrated non-fentanyl compounds can interfere with this particular immunoassay.
The practical implication is straightforward: a result depends partly on how the specimen was prepared. A small amount of powder in too little water can produce a highly concentrated solution. Greater dilution may reduce interference, although dilution also has to preserve adequate sensitivity for the target analyte. The correct preparation instructions for the specific strip and use case therefore matter.
Immunoassays are designed around molecular recognition, but antibody selectivity is not absolute. A compound with weak affinity may be irrelevant at low concentration and become important when it is present at a concentration many orders of magnitude higher than the target cutoff. This is a classic analytical-toxicology problem: specificity is a property of the assay under defined conditions, not an unlimited guarantee that no other chemical can affect the signal.
A defensible review should identify the strip manufacturer and cutoff, determine whether the procedure was validated for the specimen type, reconstruct the dilution, preserve photographs and timing information, and ask whether a blank, positive control, or confirmatory test was performed. The exact claim also matters. A strip may be useful for rapid risk communication while remaining insufficient for a legal conclusion about chemical identity.
This was a controlled laboratory study of one commercial strip format and selected compounds. It did not test every product, adulterant, mixture, pH, temperature, or real-world specimen. Its findings should not be generalized automatically to all fentanyl test strips. Nor should the study be used to dismiss a positive result without examining the actual preparation and any confirmatory evidence.
MDMA can produce a false-positive response on the tested fentanyl strip when present in a highly concentrated solution. The lesson is not that fentanyl strips are useless; it is that screening results must be interpreted within the analytical conditions that produced them. Dilution, matrix, cross-reactivity, and confirmation are central to any scientifically sound conclusion.
Lockwood T-L.E., Vervoordt A., Lieberman M. “High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips.” Harm Reduction Journal (2021). DOI: 10.1186/s12954-021-00478-4. PubMed PMID 33750405.